Clinical trial

CHARACTERISE - A Cross-sectional, Observational Study to Characterise the Transition to Dolutegravir-based Regimens in South Africa in Terms of the Emergence of Obesity, Viral Re-suppression and Integration Into Routine Programme Care

NCT05502692

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2022-07-12

PhaseN/A

Study timeline

Study start (actual)2022-07-12Date precision: day

Registry last updated2023-05-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Dolutegravirunresolved

Interventions

CHARACTERISEBEHAVIORAL

Sponsors & collaborators

University of Witwatersrand, South Africalead sponsor

UNITAIDcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05502692 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.